Tetrahydrocannabivarin (CRM) is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects. Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity.
Cannabispirol has a weak antibacterial effect which is more definite on plasmid carrying bacteria than plasmidless ones, and inhibits intercellular plasmid transfer and transforming activity of plasmid DNA.
Cannabisin B possesses considerable antiproliferative activity and that it may be utilised as a promising chemopreventive agent against hepatoblastoma disease. It induces autophagic cell death by inhibiting the AKT/mTOR pathway and S phase cell cycle arre